Tejas Savant
Stock Analyst at Morgan Stanley
(2.36)
# 2,425
Out of 5,182 analysts
245
Total ratings
42.36%
Success rate
-1%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $33.09 | +11.82% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $17.71 | +7.28% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $5.78 | +73.01% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $55.00 | +27.27% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $207.28 | +20.61% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $54.06 | +10.99% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $469.21 | +42.79% | 16 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $157.77 | +67.97% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $22.43 | -10.83% | 16 | Dec 2, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $11 → $16 | $14.27 | +12.12% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $135.78 | -22.67% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $7.96 | +50.75% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $9.44 | -15.25% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.62 | +51.52% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $10.35 | -32.37% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.73 | +34.05% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.80 | +337.50% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.60 | +25.00% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.70 | +312.37% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.70 | +122.22% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $5.32 | +87.97% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.53 | +8.70% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.03 | +392.61% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $87.60 | -16.67% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $165.78 | +50.80% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $11.08 | +802.53% | 5 | May 12, 2022 |
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $33.09
Upside: +11.82%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $17.71
Upside: +7.28%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $5.78
Upside: +73.01%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $55.00
Upside: +27.27%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $207.28
Upside: +20.61%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $54.06
Upside: +10.99%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $469.21
Upside: +42.79%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $157.77
Upside: +67.97%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $22.43
Upside: -10.83%
Adaptive Biotechnologies
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $14.27
Upside: +12.12%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $135.78
Upside: -22.67%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $7.96
Upside: +50.75%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $9.44
Upside: -15.25%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.62
Upside: +51.52%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $10.35
Upside: -32.37%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.73
Upside: +34.05%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.80
Upside: +337.50%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.60
Upside: +25.00%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.70
Upside: +312.37%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.70
Upside: +122.22%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $5.32
Upside: +87.97%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.53
Upside: +8.70%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.03
Upside: +392.61%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $87.60
Upside: -16.67%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $165.78
Upside: +50.80%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $11.08
Upside: +802.53%